Pharmaceutical Insights

24 April 2008

Welcome to the April edition of Pharma Insights. In this edition, we consider tips and tricks for sponsors of prescription medicines when designing educational campaigns for the general public, bearing in mind Medicines Australia's Code of Conduct.

We also look at the Productivity Commissioner's recent recommendations about improvements to the current Australian consumer policy framework, and the development in th EU and UK in relation to the collective redress debate.

In Patent Law we consider the impact of three recent decisions from the Federal Court on the courts' granting of interlocutory injunctions for the infringement of pharmaceutical patents.

Educator or promoter - Are you at risk of an identity crisis?

By Jocelyn Kellam and Alexandra Martin.

Sponsors of prescription medicines need to be careful when designing educational campaigns for the general public. Jocelyn Kellam and Alexandra Martin search for some guidance in recent Medicines Australia decisions.

Increased transparency for corporate sponsorship of doctors' education

By Greg Williams and Teresa Schafer.

In a world-first move, Medicines Australia published its first report of medical education events held or sponsored by its member companies. Greg Williams and Dr Teresa Baker examine its findings and what they mean for the pharmaceutical industry.

Is a unified consumer law in sight?

By Andrew Morrison, Sara Dennis and David Boots .

Harmonised consumer product safety laws are back on the agenda. Andrew Morrison, Sara Dennis and David Boots look at the most recent set of proposals.

Pharmaceutical patent infringement - interlocutory injunctions now easier to obtain

By Nicholas Tyacke.

Australian courts' traditional reluctance to grant an interlocutory injunction against the infringement of a pharmaceutical patent might be on the wane, says Nicholas Tyacke.

To view claytonutz.com correctly, you should upgrade your browser